This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Derma Sciences Reports Third Quarter 2012 Financial Results

Stocks in this article: DSCI

“Our 54-person domestic field sales organization is beginning to hit its stride and we are very pleased to report 17% sequential-quarter sales growth in advanced wound care products with the same number of sales reps in both periods. We continue to expect 30% to 40% advanced wound care sales growth in 2013, and as a result our operating business, excluding DSC127 development expenses, is expected to achieve positive cash flow. In addition, as a result of the increase in our higher-margined advanced wound care products, which now account for more than one-third of net sales, our gross margin increased by more than five percentage points to 35.2% in the third quarter versus the prior year.

“As promised, revenue from advanced wound care products other than TCC products grew 36% during the quarter and 30% year-to-date, in line with our expectations for organic growth. We are very pleased that following the integration of MedEfficiency, revenues for TCC products grew 14% in the current quarter over the second quarter. Our TCC products, along with the MEDIHONEY family of dressings, are anchoring our advanced wound care product portfolio. In fact, MEDIHONEY has performed so well, that we will make a $1.0 million milestone payment to Comvita on November 30 th, based on reaching $10.0 million in MEDIHONEY sales.”

Mr. Quilty continued, “Last month we held a positive and constructive meeting with the FDA to discuss our drug candidate DSC127 and we expect to submit a final protocol for Phase 3 development to the FDA by the end of the month. We remain on track to begin studies with DSC127 for the treatment of diabetic foot ulcers by the end of the year.”

Mr. Quilty added, “Our traditional wound care products performed as expected during the quarter, with growth driven by first-aid products, and contributed positive cash flow to support our advanced wound care efforts. While this business will fluctuate from quarter to quarter, we are on track to meet our annual sales growth objective of 2% to 4%.”

2 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,642.82 +285.95 1.65%
S&P 500 2,047.43 +34.54 1.72%
NASDAQ 4,730.1960 +85.8840 1.85%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs